MA29034B1 - Posologie d'un agoniste du recepteur s1p - Google Patents

Posologie d'un agoniste du recepteur s1p

Info

Publication number
MA29034B1
MA29034B1 MA29926A MA29926A MA29034B1 MA 29034 B1 MA29034 B1 MA 29034B1 MA 29926 A MA29926 A MA 29926A MA 29926 A MA29926 A MA 29926A MA 29034 B1 MA29034 B1 MA 29034B1
Authority
MA
Morocco
Prior art keywords
dosage
receptor agonist
agonist
receptor
Prior art date
Application number
MA29926A
Other languages
English (en)
French (fr)
Inventor
John M Kovarik
Silke Appel-Dingemanse
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36046868&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA29034(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA29034B1 publication Critical patent/MA29034B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Storage Device Security (AREA)
MA29926A 2004-11-29 2007-05-22 Posologie d'un agoniste du recepteur s1p MA29034B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US63148304P 2004-11-29 2004-11-29

Publications (1)

Publication Number Publication Date
MA29034B1 true MA29034B1 (fr) 2007-11-01

Family

ID=36046868

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29926A MA29034B1 (fr) 2004-11-29 2007-05-22 Posologie d'un agoniste du recepteur s1p

Country Status (21)

Country Link
US (3) US20090275553A1 (https=)
EP (3) EP2384749A1 (https=)
JP (4) JP2008521827A (https=)
KR (4) KR20140095109A (https=)
CN (2) CN102600472A (https=)
AU (1) AU2005309378B2 (https=)
BR (1) BRPI0518674A2 (https=)
CA (1) CA2589265A1 (https=)
ES (1) ES2495690T3 (https=)
IL (2) IL183134A0 (https=)
MA (1) MA29034B1 (https=)
MX (1) MX2007006373A (https=)
NO (2) NO20072401L (https=)
NZ (2) NZ590054A (https=)
PL (1) PL1819326T3 (https=)
PT (1) PT1819326E (https=)
RU (2) RU2478384C2 (https=)
SG (2) SG158096A1 (https=)
TN (1) TNSN07209A1 (https=)
WO (1) WO2006058316A1 (https=)
ZA (1) ZA200703328B (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007001661A (es) 2004-08-13 2007-04-23 Praecis Pharm Inc Metodos y composiciones para modular la actividad del receptor de esfingosina -1 fosfato (sip).
KR20140095109A (ko) * 2004-11-29 2014-07-31 노파르티스 아게 Ｓ１ｐ 수용체 효능제의 투여 용법
SI2295049T1 (sl) * 2005-09-09 2015-03-31 Novartis Ag Zdravljenje avtoimunskih bolezni
GB0612721D0 (en) * 2006-06-27 2006-08-09 Novartis Ag Organic compounds
ES2707576T3 (es) 2007-05-04 2019-04-04 Novartis Ag Uso de modulador del receptor S1P
HUE033168T2 (en) * 2008-03-17 2017-11-28 Actelion Pharmaceuticals Ltd Dosage regimen for selective SIP1 receptor agonist
NZ589412A (en) * 2008-05-20 2012-11-30 Kyorin Seiyaku Kk Use of a sphingosine-1-phosphate (S1P) agonist for maintance of induced remission of autoimmune or inflammatory diseases after inital treatment
US9149459B2 (en) 2008-07-23 2015-10-06 Novartis Ag Sphingosine 1 phosphate receptor modulators and their use to treat muscle inflammation
ES2526119T3 (es) 2008-08-18 2015-01-07 Novartis Ag Derivado de azetidina para el tratamiento de neuropatías periféricas
PT2676953T (pt) * 2008-12-18 2017-06-29 Novartis Ag Sal hemifumarato de ácido 1-[4-[1-(4-ciclo-hexil-3-trifluorometil-benziloxi-imino)-etil]-2-etil-benzil]-azetidino-3-carboxílico para utilização no tratamento de doenças mediadas por linfócitos
CA2747558A1 (en) * 2008-12-18 2010-07-15 Novartis Ag New salts
CN102256942B (zh) * 2008-12-18 2013-07-24 诺瓦提斯公司 1-(4-{1-[(e)-4-环己基-3-三氟甲基-苄氧基亚氨基]-乙基}-2-乙基-苄基)-氮杂环丁烷-3-甲酸的多晶型物
CN105213372A (zh) * 2008-12-22 2016-01-06 诺华股份有限公司 S1p受体激动剂的给药方案
AU2015275246B2 (en) * 2008-12-22 2018-02-01 Novartis Ag Dosage regimen for a S1P receptor agonist
RS66784B9 (sr) * 2008-12-22 2025-08-29 Novartis Ag Režim doziranјa agonista s1p receptora
EP2482810A2 (en) * 2009-09-29 2012-08-08 Novartis AG Dosage regimen of an s1p receptor modulator
US20110124605A1 (en) * 2009-11-20 2011-05-26 Shreeram Aradhye Use of an S1P Receptor Agonist
US8791100B2 (en) 2010-02-02 2014-07-29 Novartis Ag Aryl benzylamine compounds
EP2566473B1 (en) * 2010-05-06 2016-01-06 Novartis AG Dosage regimen of diaryl sulfide derivatives
BR112013017302B1 (pt) 2011-01-07 2021-12-07 Novartis Ag Composição farmacêutica em fase sólida
PH12014500854A1 (en) * 2011-10-21 2021-08-09 Novartis Ag Dosage regimen for an s1p receptor modulator or agonist
MX350891B (es) 2012-08-17 2017-09-22 Actelion Pharmaceuticals Ltd Proceso para la preparacion de (2z,5z)-5-(3-cloro-4-((r)-2,3-dihid roxipropoxi) bencilideno)-2-(propilimino)-3-(o-tolil) tiazolidin-4-ona y el intermediario usado en dicho proceso.
CN102887829B (zh) * 2012-09-05 2014-07-02 中国科学院上海药物研究所 芬戈莫德粘酸盐及其晶体的制备方法和用途
US10675254B2 (en) 2013-10-11 2020-06-09 Teikoku Seiyaku Co., Ltd. Sphingosine-1-phosphate receptor agonist iontophoretic devices and methods of using the same
JP6401257B2 (ja) 2013-10-11 2018-10-10 テイコク ファーマ ユーエスエー インコーポレーテッド 局所用スフィンゴシン−１−リン酸受容体アゴニスト製剤及びその使用方法
MA41139B1 (fr) 2014-12-11 2026-02-27 Laboratoires Juvise Pharmaceuticals Combinaison pharmaceutique comprenant du ponesimod et son utilisation dans le traitement de la sclérose en plaque
EP4056179A1 (en) 2014-12-11 2022-09-14 Actelion Pharmaceuticals Ltd Dosing regimen for ponesimod, a selective s1p1 receptor agonist
WO2016135644A1 (en) 2015-02-26 2016-09-01 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
US10250466B2 (en) * 2016-03-29 2019-04-02 Juniper Networks, Inc. Application signature generation and distribution
US11629124B2 (en) 2017-03-09 2023-04-18 Novartis Ag Solid forms comprising an oxime ether compound, compositions and methods of use thereof
AU2020372647B2 (en) 2019-10-31 2026-02-05 Idorsia Pharmaceuticals Ltd Combination of a CXCR7 antagonist with an S1P1 receptor modulator

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604229A (en) 1992-10-21 1997-02-18 Yoshitomi Pharmaceutical Industries, Ltd. 2-amino-1,3-propanediol compound and immunosuppressant
DE69524962D1 (de) 1994-08-22 2002-02-14 Welfide Corp Benzolderivate und deren medizinische verwendung
ES2230571T3 (es) * 1995-12-28 2005-05-01 Mitsubishi Pharma Corporation `composicion farmaceutica destinada para la administracion topica que comprende el 2-amino-2-(2-(4-octilfenil)etil) propan-1,3-diol para el tratamiento de las enfermedades causadas por una alteracion inmunitaria.
US6476004B1 (en) * 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition
DE69840169D1 (de) * 1997-02-27 2008-12-11 Novartis Ag Arzneimittel zubereitung enthaltend 2-amino-2-ä2-(4-octylphenyl)ethylüpropane-1,3-diol, ein lecithin und ein saccharid
ATE298740T1 (de) 1997-04-04 2005-07-15 Mitsubishi Pharma Corp 2-aminopropan-1,3-diol-verbindungen, ihre medizinische anwendung und zwischenprodukte zu ihrer synthese
JPH1180026A (ja) * 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
JPH11116479A (ja) * 1997-10-10 1999-04-27 Sugen Inc 脳癌のための組み合わせ化学療法処置
WO2002006268A1 (en) 2000-07-13 2002-01-24 Sankyo Company, Limited Amino alcohol derivatives
WO2002018395A1 (en) 2000-08-31 2002-03-07 Merck & Co., Inc. Phosphate derivatives as immunoregulatory agents
EP1377593B1 (en) 2001-03-26 2005-12-28 Novartis AG 2-amino-propanol derivatives
IL157946A0 (en) * 2001-04-02 2004-03-28 Genentech Inc Combination therapy
EP1381358B1 (en) * 2001-04-02 2006-05-03 Astrazeneca AB Solid pharmaceutical composition comprising 4'-cyano-trifluoro-3-(4-fluorophenylsulphonyl) -2-hydroxy-2-methylpropiono- m toluidide and pvp
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
ES2322442T3 (es) * 2001-06-08 2009-06-22 Novartis Ag Tratamiento o profilaxis del rechazo de injertos de celulas productoras de insulina.
MXPA04002679A (es) * 2001-09-27 2004-07-30 Kyorin Seiyaku Kk Derivados de sulfuro de diarilo, sales de los mismos y agentes inmunosupresores que utilizan los mismos.
EP1431275B1 (en) * 2001-09-27 2010-04-07 Kyorin Pharmaceutical Co., Ltd. Diaryl ether derivative, addition salt thereof, and immunosuppressant
US20050070506A1 (en) 2002-01-18 2005-03-31 Doherty George A. Selective s1p1/edg1 receptor agonists
US7479504B2 (en) * 2002-01-18 2009-01-20 Merck & Co., Inc. Edg receptor agonists
ATE448193T1 (de) 2002-01-18 2009-11-15 Merck & Co Inc ßN-(BENZYL)AMINOALKYL CARBOXYLATE, PHOSPHINATE, PHOSPHONATE UND TETRAZOLE ALS EDG REZEPTORAGONISTENß
KR20080103117A (ko) * 2002-09-24 2008-11-26 노파르티스 아게 탈수초성 장애의 치료에 있어서의 스핑고신-1-포스페이트 수용체 아고니스트
BRPI0410439A (pt) 2003-05-19 2006-06-06 Irm Llc compostos e composições imunossupressoras
MY150088A (en) * 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
UA74941C2 (en) 2004-04-26 2006-02-15 Fos Internat S A A metal-thermal process for producing magnesium and vacuum induction furnace for realizing the same
WO2005113330A1 (en) 2004-05-05 2005-12-01 Adler, Richard, S. Systems and methods for protecting ship from attack on the surface or under water
WO2006041015A1 (ja) * 2004-10-12 2006-04-20 Kyorin Pharmaceutical Co., Ltd. アミノアルコール誘導体とその付加塩及び免疫抑制剤
KR20140095109A (ko) * 2004-11-29 2014-07-31 노파르티스 아게 Ｓ１ｐ 수용체 효능제의 투여 용법
GT200600350A (es) * 2005-08-09 2007-03-28 Formulaciones líquidas

Also Published As

Publication number Publication date
IL183134A0 (en) 2008-04-13
TNSN07209A1 (en) 2008-11-21
JP2015061883A (ja) 2015-04-02
US20090275553A1 (en) 2009-11-05
EP1819326A1 (en) 2007-08-22
CN101068536A (zh) 2007-11-07
EP2359821A1 (en) 2011-08-24
RU2012141951A (ru) 2014-04-10
ES2495690T3 (es) 2014-09-17
JP2008521827A (ja) 2008-06-26
BRPI0518674A2 (pt) 2008-12-02
KR20140095109A (ko) 2014-07-31
KR20070085465A (ko) 2007-08-27
AU2005309378B2 (en) 2010-02-11
IL223502A0 (en) 2013-02-03
HK1109057A1 (en) 2008-05-30
SG158096A1 (en) 2010-01-29
RU2007124327A (ru) 2009-01-10
WO2006058316A1 (en) 2006-06-01
EP2384749A1 (en) 2011-11-09
US20150087720A1 (en) 2015-03-26
EP1819326B1 (en) 2014-07-02
ZA200703328B (en) 2008-08-27
KR20150028858A (ko) 2015-03-16
RU2478384C2 (ru) 2013-04-10
NZ554720A (en) 2011-04-29
JP2013129664A (ja) 2013-07-04
KR20130041385A (ko) 2013-04-24
MX2007006373A (es) 2007-06-20
CN102600472A (zh) 2012-07-25
AU2005309378A1 (en) 2006-06-01
NZ590054A (en) 2012-07-27
US20120071446A1 (en) 2012-03-22
JP2012107059A (ja) 2012-06-07
NO20072401L (no) 2007-06-22
NO20121305L (no) 2007-06-22
PT1819326E (pt) 2014-09-25
CA2589265A1 (en) 2006-06-01
PL1819326T3 (pl) 2014-12-31
CN101068536B (zh) 2012-12-05
SG187468A1 (en) 2013-02-28

Similar Documents

Publication Publication Date Title
MA29034B1 (fr) Posologie d'un agoniste du recepteur s1p
FR20C1022I2 (fr) Posologie d'un agoniste du recepteur s1p
FR25C1012I1 (fr) Posologie d'un agoniste du récepteur s1p
MA28902B1 (fr) Agonistes des recepteurs beta2 adrenergiques diaminiques
EP2049110A4 (en) BRAZED DIAZEPANOREXINE RECEPTOR ANTAGONISTS
FR16C0018I2 (fr) Combinaison pharmaceutiques d'un antagoniste de recepteur d'angiotensine et d'un inhibiteur de nep
MA28359A1 (fr) Antagonistes du recepteur a l'hydroisoindoline tachykinine
EP1641781A4 (en) BENZODIAZEPINE-CGRP Receptor Antagonists
EP1765805A4 (en) CGRP RECEPTOR ANTAGONISTS
DK2080514T3 (da) Manipulationssikre orale farmaceutiske doseringsformer omfattende et opioidanalgetikum
EP2120575A4 (en) AGONISTS AND ANTAGONISTS OF SPHINGOSINE-1-PHOSPHATE RECEPTORS
EP1625123A4 (en) 3- (2-AMINO-1-AZACYCLYL) -5-ARYL-1,2,4-OXADIAZOLE AS S1P RECEPTOR AGONISTS
NO20051871D0 (no) Opioid reseptorantagonister
EP1799865A4 (en) PROCESS FOR THE ADMINISTRATION OF ILOPERIDONE
EP1868985A4 (en) GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS USING SUCH COMPOUNDS AND METHOD FOR THEIR USE
EP2134342A4 (en) MONOCYCLIC ANILID SPIROLACTAM CGRP RECEPTOR ANTAGONISTS
MA28089A1 (fr) AGONISTES ETHYLAMINO AMINOSUBSTITUES DU RECEPTEUR ß2 ADRENERGIQUE
EP1827421A4 (en) Estrogen receptor modulators
NO20055143D0 (no) Doseringsformer innbefattende AG013736
EP2146572A4 (en) BICYCLIC HETEROCYCLIC ANILID CGRP RECEPTOR ANTAGONISTS
EP1799672A4 (en) CGRP RECEPTOR ANTAGONIST
EP2249833A4 (en) PROGRUGS OF CGRP RECEPTOR ANTAGONISTS
DK2091938T3 (da) Piperidinylaminopyridaziner og anvendelse deraf som hurtigt opløsende antagonister af dopamin-2-receptorer
EP1808446A4 (en) IL-18 RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITION WITH THE ANTAGONIST
EP1751175A4 (en) ANTAGONISTS OF THE INTERLEUKIN-1 RECEPTOR, COMPOSITIONS AND TREATMENT PROCEDURES